Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells.
Yacoub A, Hamed HA, Allegood J, Mitchell C, Spiegel S, Lesniak MS, Ogretmen B, Dash R, Sarkar D, Broaddus WC, Grant S, Curiel DT, Fisher PB, Dent P. Yacoub A, et al. Among authors: ogretmen b. Cancer Res. 2010 Feb 1;70(3):1120-9. doi: 10.1158/0008-5472.CAN-09-4043. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103619 Free PMC article.
Crosstalk between pro-survival sphingolipid metabolism and complement signaling induces inflammasome-mediated tumor metastasis.
Janneh AH, Kassir MF, Atilgan FC, Lee HG, Sheridan M, Oleinik N, Szulc Z, Voelkel-Johnson C, Nguyen H, Li H, Peterson YK, Marangoni E, Saatci O, Sahin O, Lilly M, Atkinson C, Tomlinson S, Mehrotra S, Ogretmen B. Janneh AH, et al. Among authors: ogretmen b. Cell Rep. 2022 Dec 6;41(10):111742. doi: 10.1016/j.celrep.2022.111742. Cell Rep. 2022. PMID: 36476873 Free PMC article.
Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma.
Kang Y, Sundaramoorthy P, Gasparetto C, Feinberg D, Fan S, Long G, Sellars E, Garrett A, Tuchman SA, Reeves BN, Li Z, Liu B, Ogretmen B, Maines L, Ben-Yair VK, Smith C, Plasse T. Kang Y, et al. Among authors: ogretmen b. Ann Hematol. 2023 Feb;102(2):369-383. doi: 10.1007/s00277-022-05056-7. Epub 2022 Dec 3. Ann Hematol. 2023. PMID: 36460794 Clinical Trial.
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Park MA, Mitchell C, Zhang G, Yacoub A, Allegood J, Häussinger D, Reinehr R, Larner A, Spiegel S, Fisher PB, Voelkel-Johnson C, Ogretmen B, Grant S, Dent P. Park MA, et al. Among authors: ogretmen b. Cancer Res. 2010 Aug 1;70(15):6313-24. doi: 10.1158/0008-5472.CAN-10-0999. Epub 2010 Jul 14. Cancer Res. 2010. PMID: 20631069 Free PMC article.
A serotype 5/3 adenovirus expressing MDA-7/IL-24 infects renal carcinoma cells and promotes toxicity of agents that increase ROS and ceramide levels.
Park MA, Hamed HA, Mitchell C, Cruickshanks N, Dash R, Allegood J, Dmitriev IP, Tye G, Ogretmen B, Spiegel S, Yacoub A, Grant S, Curiel DT, Fisher PB, Dent P. Park MA, et al. Among authors: ogretmen b. Mol Pharmacol. 2011 Mar;79(3):368-80. doi: 10.1124/mol.110.069484. Epub 2010 Nov 30. Mol Pharmacol. 2011. PMID: 21119025 Free PMC article.
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.
Saddoughi SA, Garrett-Mayer E, Chaudhary U, O'Brien PE, Afrin LB, Day TA, Gillespie MB, Sharma AK, Wilhoit CS, Bostick R, Senkal CE, Hannun YA, Bielawski J, Simon GR, Shirai K, Ogretmen B. Saddoughi SA, et al. Among authors: ogretmen b. Clin Cancer Res. 2011 Sep 15;17(18):6097-105. doi: 10.1158/1078-0432.CCR-11-0930. Epub 2011 Jul 26. Clin Cancer Res. 2011. PMID: 21791630 Free PMC article. Clinical Trial.
146 results